Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2, open-label, non-randomized multicenter study to assess the safety and
efficacy of ibrutinib and lenalidomide in combination with DA-EPOCH-R in subjects with
relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL).